<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Congenital and inherited hyperpigmentation disorders
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Congenital and inherited hyperpigmentation disorders
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Congenital and inherited hyperpigmentation disorders
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Neelam Vashi, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Roopal V Kundu, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Erik Stratman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3838406120">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperpigmentation is the darkening or increase in the natural color of the skin, usually due to an increased deposition of melanin (hypermelanosis) in the epidermis and/or dermis. Less frequently, it may be caused by the deposition in the dermis of endogenous or exogenous pigments, such as hemosiderin, iron, or heavy metals.
        </p>
        <p>
         Hyperpigmentation is a feature of a multitude of clinical conditions, ranging from normal variations of skin color to acquired and inherited syndromes, and is one of the most common reasons for dermatologic consultation, particularly in patients with darkly pigmented skin [
         <a href="#rid1">
          1-3
         </a>
         ]. Although hyperpigmentation is not harmful, it can cause significant cosmetic disfigurement and become a persistent psychosocial burden for the patient, due to the limited efficacy of the available treatments.
        </p>
        <p>
         This topic will review the approach to the patient with congenital and inherited hyperpigmentation disorders. Incontinentia pigmenti, pigmentary mosaicism, and acquired disorders of pigmentation, including melasma, are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">
          "Incontinentia pigmenti"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/97404.html" rel="external">
          "Pigmentary mosaicism (hypomelanosis of Ito)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">
          "Acquired hyperpigmentation disorders"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">
          "Melasma: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2664884664">
         <span class="h1">
          PATHOPHYSIOLOGY OF SKIN PIGMENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H3035299971">
         <span class="h2">
          Determinants of skin color
         </span>
         <span class="headingEndMark">
          —
         </span>
         The color of human skin is mainly determined by the two types of melanin, the black-brown eumelanin and the yellow-red pheomelanin, which are present in individuals of all skin colors, though their ratio is highly variable and determines the hue of the skin [
         <a href="#rid4">
          4-6
         </a>
         ]. Melanin is produced by melanocytes, specialized cells of neural crest origin that reside in the basal layer of the epidermis. The biosynthesis of melanin occurs in lysosome-like organelles called melanosomes, which are transported to the cell periphery and transferred from the dendritic tips of the melanocytes to the surrounding keratinocytes [
         <a href="#rid7">
          7
         </a>
         ]. Each melanocyte is associated with up to 40 basal keratinocytes to form the epidermal melanin unit [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Differences in the number, size, and aggregation of melanosomes within the melanocytes and keratinocytes, but not in the overall number of melanocytes, contribute to ethnic differences in skin color [
         <a href="#rid9">
          9,10
         </a>
         ]. Darkly pigmented skin has a higher content of melanin, higher eumelanin-to-pheomelanin ratio, nonaggregated and larger melanosomes,
         <sup>
         </sup>
         and slower melanosome degradation within the keratinocytes [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1644998200">
         <span class="h2">
          Genetic basis of pigmentary disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         The biochemical pathway of melanogenesis is under complex genetic control, with hundreds of genes and genetic polymorphisms involved in the modulation of type and distribution of pigmentation [
         <a href="#rid7">
          7,12,13
         </a>
         ]. However, only a few of them have been identified as the cause of specific monogenic hyperpigmentation disorders [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Mutations affecting genes involved in the differentiation and migration of melanocyte precursors in the neural crest or in the proliferation and activity of mature melanocytes may be involved in the pathogenesis of hyperpigmentation associated with inherited syndromes [
         <a href="#rid7">
          7
         </a>
         ]. The genetic defects associated with a number of inherited and syndromic hyperpigmentation disorders are summarized in the table  (
         <a class="graphic graphic_table graphicRef112464" href="/z/d/graphic/112464.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3242894543">
         <span class="h1">
          PATIENT EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of hyperpigmentation disorders may be challenging. An algorithmic approach to the diagnosis based upon history and clinical parameters is shown in the figure  (
         <a class="graphic graphic_algorithm graphicRef93949" href="/z/d/graphic/93949.html" rel="external">
          algorithm 1
         </a>
         ). In most cases, the initial patient evaluation involves a detailed personal and family medical history and a complete physical examination, which should include a careful search for additional cutaneous and extracutaneous signs and symptoms.
        </p>
        <p>
         Questions that may be useful for the evaluation of patients with hyperpigmentation disorders include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the disorder congenital or acquired?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the disorder isolated or part of a syndrome?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the pigmentation localized or diffuse?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the pigmentation well circumscribed or ill defined?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Does the pigmentation have a pattern (eg, linear, reticular)?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the pigmentation associated with inflammation and/or prior cutaneous injury?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the pigmentation stable, progressing, or regressing?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2863471584">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         A detailed family history may be helpful to determine whether the disorder is congenital and isolated or inherited and, in the latter case, what is the probable inheritance pattern [
         <a href="#rid14">
          14
         </a>
         ]. However, although congenital or inherited hyperpigmentation disorders are often present at birth, history may be misleading since parents/caregivers may not have noted it for months or longer.
        </p>
        <p>
         The course of the disorder is also a useful parameter in the clinical diagnosis of hyperpigmentation disorders. Inherited disorders of hyperpigmentation are often stable, whereas most acquired forms show progression or regression.
        </p>
        <p class="headingAnchor" id="H2059512450">
         <span class="h2">
          Skin examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with hyperpigmentation disorders, a complete skin examination should be performed under visible light and Wood's light. Important clinical parameters include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extent of the pigmentary abnormality (localized versus diffuse)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Color hue (shades of brown/black, slate-gray/blue)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morphology of individual lesions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distribution (eg, dermatomal, following Blaschko lines)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pattern (eg, linear, reticular, nonfigurate)
        </p>
        <p>
        </p>
        <p>
         A careful search for associated cutaneous and extracutaneous signs and symptoms may provide important clues to the diagnosis in patients with hyperpigmentation disorders associated with genetic syndromes.
        </p>
        <p class="headingAnchor" id="H2559734590">
         <span class="h2">
          Wood's light examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wood's light, also known as "black light," is ultraviolet A light with a peak emission at 365 nm [
         <a href="#rid15">
          15
         </a>
         ]. The patient is examined in a darkened room with the light source held at 10 to 15 cm from the skin. Wood's light can be helpful in determining disease extent (eg, sun-exposed areas, areas previously involved by inflammatory processes, dermatomal distribution, following Blaschko lines) and whether the pigment deposition is epidermal, dermal, or mixed. However, its effectiveness is limited in patients with darkly pigmented skin [
         <a href="#rid16">
          16,17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidermal hypermelanosis
         </strong>
         – Under natural light, epidermal hypermelanosis appears light brown to dark brown in color. The pigmentation, as well as the contrast between involved and uninvolved skin, is enhanced when viewed under a Wood's lamp.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dermal hypermelanosis
         </strong>
         – Under natural light, dermal hypermelanosis has a bluish or ashen gray hue with margins less defined than epidermal hypermelanosis. The pigmentation is not accentuated by the Wood's light.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed hypermelanosis
         </strong>
         – Mixed hypermelanosis appears light to dark brown under natural light, whereas Wood's light examination will show enhancement in some areas and none in others.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1944950059">
         <span class="h2">
          Dermoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermoscopy, also known as dermatoscopy, epiluminescence microscopy, or skin surface microscopy, is a noninvasive in vivo technique that has been traditionally used to evaluate pigmented lesions (ie, nevi). However, it also has a role in helping to identify the depth of melanin deposition, from superficial/epidermal to dermal [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidermal hypermelanosis
         </strong>
         – Pseudoreticular pigment network
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dermal hypermelanosis
         </strong>
         – Gray dots and/or blotches, often perifollicular or periadnexal
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed hypermelanosis
         </strong>
         – Combination of above patterns
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3979939753">
         <span class="h2">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A skin biopsy for histopathologic evaluation is not routinely performed for the diagnosis of hyperpigmentation disorders. However, it may be necessary when the clinical diagnosis is uncertain. Standard stains (eg, hematoxylin and eosin, Fontana-Masson silver stain) and histochemical techniques (eg, Mart-1, Melan-A) are used to evaluate the number and localization of melanocytes and melanin granules in the epidermis and dermis. The main histopathologic findings in selected acquired and congenital or inherited hyperpigmentation disorders are summarized in the table  (
         <a class="graphic graphic_table graphicRef95321" href="/z/d/graphic/95321.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2785915602">
         <span class="h1">
          CIRCUMSCRIBED HYPERPIGMENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H2246529435">
         <span class="h2">
          Congenital dermal melanocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital dermal melanocytosis is a group of hyperpigmentation disorders characterized by the presence of melanin-producing melanocytes in the dermis. They are most commonly seen in Asian populations and include the nevus of Ito  (
         <a class="graphic graphic_picture graphicRef94990" href="/z/d/graphic/94990.html" rel="external">
          picture 1
         </a>
         ), nevus of Ota  (
         <a class="graphic graphic_picture graphicRef94993" href="/z/d/graphic/94993.html" rel="external">
          picture 2
         </a>
         ), and the so-called Mongolian spots  (
         <a class="graphic graphic_picture graphicRef77805" href="/z/d/graphic/77805.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
         The congenital dermal melanocytoses are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">
          "Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Dermal melanocytoses'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">
          "Skin lesions in the newborn and infant", section on 'Dermal melanocytosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2136293983">
         <span class="h2">
          Café-au-lait macules
         </span>
         <span class="headingEndMark">
          —
         </span>
         Café-au-lait macules are sharply demarcated, hyperpigmented macules or patches that are typically two to three shades darker than the normal, uninvolved skin  (
         <a class="graphic graphic_picture graphicRef50599" href="/z/d/graphic/50599.html" rel="external">
          picture 4
         </a>
         ). They vary in size from a few millimeters to more than 10 cm and can occur anywhere on the body. (See
         <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">
          "Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Café-au-lait macule'
         </a>
         .)
        </p>
        <p>
         Café-au-lait macules are often present at birth or appear in the first months of life. Isolated lesions are common and usually have no clinical significance. In contrast, multiple café-au-lait macules may represent the cutaneous marker of underlying genetic disorders such as neurofibromatosis type 1 and McCune-Albright syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'
         </a>
         .)
        </p>
        <p>
         Café-au-lait macules are difficult to treat. Partial clearance may be achieved with laser treatment, but recurrence is common [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">
          "Laser and light therapy for cutaneous hyperpigmentation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1381354041">
         <span class="h2">
          Nevus spilus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nevus spilus, also called speckled lentiginous nevus, is a hyperpigmented macule or patch with superimposed darker brown macules and papules  (
         <a class="graphic graphic_picture graphicRef64780" href="/z/d/graphic/64780.html" rel="external">
          picture 5
         </a>
         ). The darker macules and papules may consist of junctional, compound, Spitz, atypical, or blue nevi. (See
         <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">
          "Congenital melanocytic nevi", section on 'Speckled lentiginous nevus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4277182963">
         <span class="h2">
          Segmental pigmentation disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Segmental pigmentation disorder is a form of pigmentary mosaicism characterized by hypo- or hyperpigmented patches with a segmental pattern that has been referred to as block-like, flag-like, or resembling a checkerboard [
         <a href="#rid20">
          20
         </a>
         ]. Any site can be affected, but the trunk is favored. The shape is frequently quadrangular, and the margins may be serrated [
         <a href="#rid21">
          21
         </a>
         ]. The cutaneous findings can be more prominent in individuals with darkly pigmented skin [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97404.html" rel="external">
          "Pigmentary mosaicism (hypomelanosis of Ito)", section on 'Segmental pigmentation disorder'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4128335738">
         <span class="h1">
          DIFFUSE LINEAR HYPERPIGMENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H419754671">
         <span class="h2">
          Pigmentary demarcation lines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The color of skin normally exhibits variation in hue and intensity at various sites of the body [
         <a href="#rid23">
          23
         </a>
         ]. In all skin types, the dorsal skin surfaces are more pigmented than the ventral surfaces. Pigmentary demarcation lines (also known as Futcher or Voigt lines) are a frequent finding, particularly in individuals with darkly pigmented skin. They are symmetric, bilateral, and are present from infancy to adulthood. Eight types of pigmentary demarcation lines (A to H) have been described [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type A – Lateral aspect of upper anterior portion of arms, across the pectoral area  (
         <a class="graphic graphic_picture graphicRef95259 graphicRef95260" href="/z/d/graphic/95259.html" rel="external">
          picture 6A-B
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type B – Posterior medial portion of lower limb  (
         <a class="graphic graphic_picture graphicRef96050" href="/z/d/graphic/96050.html" rel="external">
          picture 7
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type C – Vertical hypopigmentation line in pre- and parasternal areas
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type D – Posterior medial area of spine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type E – Bilateral aspect of chest, from the mid-third of clavicle to periareolar skin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type F – A straight or curved convex line sharply demarcating a relatively darker zone from a light area over the face; a V-shaped hyperpigmented line between the malar prominence and the temple  (
         <a class="graphic graphic_picture graphicRef95256" href="/z/d/graphic/95256.html" rel="external">
          picture 8
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type G – W-shaped hyperpigmented lines between the malar prominence and the temple  (
         <a class="graphic graphic_picture graphicRef95257" href="/z/d/graphic/95257.html" rel="external">
          picture 9
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type H – Linear bands of hyperpigmentation from the angle of the mouth to the lateral aspects of the chin  (
         <a class="graphic graphic_picture graphicRef95258" href="/z/d/graphic/95258.html" rel="external">
          picture 10
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Type A or Futcher lines are the most common type. They appear as sharp, easily recognizable lines located on the lateral aspect of the anterior portion of the upper arm, delineating the contrast in depth of color between the lateral and medial side of the arm  (
         <a class="graphic graphic_picture graphicRef95259" href="/z/d/graphic/95259.html" rel="external">
          picture 6A
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1779304057">
         <span class="h2">
          Incontinentia pigmenti
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incontinentia pigmenti, also known as Bloch-Sulzberger syndrome (MIM #308300), is an X-linked dominant multisystem disease that is usually lethal in males. It presents in newborns with linear papules and vesicles  (
         <a class="graphic graphic_picture graphicRef58769 graphicRef78272" href="/z/d/graphic/58769.html" rel="external">
          picture 11A-B
         </a>
         ).
        </p>
        <p>
         Within weeks or months, these lesions progress to verrucous streaks, which typically resolve leaving streaks of hyperpigmentation  (
         <a class="graphic graphic_picture graphicRef89806 graphicRef53297" href="/z/d/graphic/89806.html" rel="external">
          picture 12A-B
         </a>
         ). At three to six months of age, hyperpigmented whorls and swirls appear along Blaschko lines  (
         <a class="graphic graphic_picture graphicRef89807" href="/z/d/graphic/89807.html" rel="external">
          picture 13
         </a>
         ).
        </p>
        <p>
         By the second or third decade of life or sooner, the hyperpigmented whorls may gradually become hypopigmented and may leave subtle atrophy. Incontinentia pigmenti is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">
          "Incontinentia pigmenti"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3786754464">
         <span class="h2">
          Linear and whorled nevoid hypermelanosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Linear and whorled nevoid hypermelanosis, also called linear nevoid hypo-/hyperpigmentation, is a clinical manifestation of pigmentary mosaicism (previously known as hypomelanosis of Ito) characterized by hyperpigmented macules in a streaky configuration along the lines of Blaschko, mainly located on the trunk and limbs  (
         <a class="graphic graphic_picture graphicRef93850 graphicRef93849" href="/z/d/graphic/93850.html" rel="external">
          picture 14A-B
         </a>
         ) [
         <a href="#rid25">
          25,26
         </a>
         ]. The pigmentation is present at birth or appears in the first few weeks of life, progresses for one to two years, and then stabilizes. In some patients, hypo- and hyperpigmented macules coexist. A quality-switched (Q-switched) 694 nm ruby laser has been used to treat linear and whorled nevoid hypermelanosis in a single case report [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97404.html" rel="external">
          "Pigmentary mosaicism (hypomelanosis of Ito)"
         </a>
         .)
        </p>
        <p>
         There are isolated reports of associated extracutaneous abnormalities, involving mostly the central nervous system, musculoskeletal system, and heart. The presence of genetic mosaicism has been documented in a few patients (mosaic trisomy 7, 14, 18, 20, and X-chromosomal mosaicism) [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p>
         The diagnosis is clinical. Histology is nonspecific and shows increased pigmentation of the basal layer with prominent melanocytes and variable presence of pigmentary incontinence. The differential diagnosis includes the pigmented stage of incontinentia pigmenti and epidermal nevus. (See
         <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">
          "Incontinentia pigmenti"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13728.html" rel="external">
          "Epidermal nevus and epidermal nevus syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3797167099">
         <span class="h1">
          DIFFUSE RETICULAR HYPERPIGMENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H2059968813">
         <span class="h2">
          Dowling-Degos disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dowling-Degos disease (DDD), also known as reticulate pigmented anomaly of flexures, is a rare autosomal dominant genodermatosis associated in approximately one-half of cases with loss-of-function mutations in the gene that encodes keratin 5,
         <em>
          KRT5
         </em>
         <sup>
         </sup>
         [
         <a href="#rid31">
          31
         </a>
         ]. Mutations in
         <em>
          POFUT1
         </em>
         and
         <em>
          POGLUT1
         </em>
         (which encode the protein O-fucosyltransferase 1 and O-glucosyltransferase 1, respectively) involved in the Notch signaling pathway, have been found in affected individuals who do not have mutations in
         <em>
          KRT5
         </em>
         [
         <a href="#rid32">
          32-35
         </a>
         ]. The disease has been reported worldwide and affects all sexes equally. Onset is typically during the third to fourth decade of life.
        </p>
        <p>
         DDD is characterized by an acquired reticular hyperpigmentation that begins in the axillae and groin and later involves other body folds, including intergluteal and inframammary folds, neck, and inner aspects of the arms and thighs  (
         <a class="graphic graphic_picture graphicRef95189 graphicRef77681" href="/z/d/graphic/95189.html" rel="external">
          picture 15A-B
         </a>
         ). Generalized forms with more extensive distribution have also been described [
         <a href="#rid36">
          36
         </a>
         ]. Associated features include comedo-like lesions on the back or neck, pitted perioral or facial scars, and epidermoid cysts
         <sup>
         </sup>
         [
         <a href="#rid37">
          37
         </a>
         ]. Pruritus is a common accompanying symptom.
        </p>
        <p>
         The diagnosis is based upon the clinical features and the examination of a skin biopsy. Histology shows increased pigmentation of the basal layer and finger-like rete ridges with thinning of the suprapapillary epithelium.
        </p>
        <p>
         The differential diagnosis includes a group of related genodermatoses with reticular pigmentation, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Haber's syndrome
         </strong>
         – Haber's syndrome is characterized by a photosensitive rosacea-like facial eruption, keratotic papules, prominent comedones, pitted scars, and reticulate hyperpigmentation on the trunk, proximal extremities, and axillae [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Galli-Galli disease
         </strong>
         – Galli-Galli disease is a rare autosomal dominant disorder considered to be an allelic variant of DDD [
         <a href="#rid39">
          39-41
         </a>
         ]. It has the same clinical and histologic features of DDD except for the presence of suprabasal nondyskeratotic acantholysis on histopathology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reticulate acropigmentation of Kitamura
         </strong>
         – (see
         <a class="local">
          'Reticulate acropigmentation of Kitamura'
         </a>
         below).
        </p>
        <p>
        </p>
        <p>
         There are no effective treatments for DDD. Topical retinoids, skin-lightening agents, and laser therapy have been used in a limited number of patients with varying success
         <sup>
         </sup>
         [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2805880534">
         <span class="h2">
          Reticulate acropigmentation of Kitamura
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reticulate acropigmentation of Kitamura (RAK) is a rare genodermatosis characterized by atrophic, hyperpigmented macules with an initial acral distribution. A mutation in the
         <em>
          ADAM10
         </em>
         gene encoding a zinc metalloproteinase has been identified in a RAK family
         <sup>
         </sup>
         [
         <a href="#rid44">
          44
         </a>
         ]. RAK has been reported worldwide, but most cases are from Japan.
        </p>
        <p>
         The disease presents in childhood or adolescence with hyperpigmented, slightly depressed macules, often in a reticulate pattern, on the dorsum of the hands and feet. The distinguishing element of this disorder is the atrophic appearance of the lesions. During adulthood, the macules may darken and spread to other sites. Associated findings are pits on the palms, soles, and dorsal aspect of phalanges as well as breaks in palm and sole dermatoglyphics. Histologically, the hyperpigmented macules show epidermal atrophy and elongated rete ridges that contain increased melanin.
        </p>
        <p>
         The differential diagnosis of RAK includes other diseases presenting with reticular or punctate hyperpigmentation, such as dyskeratosis congenita, dyschromatosis universalis hereditaria, Franceschetti-Jadassohn's syndrome, and DDD. Overlapping cases of RAK and DDD have been reported [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         There are no effective therapies for RAK. Topical
         <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">
          azelaic acid
         </a>
         has been successfully used in a single case report [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2359235535">
         <span class="h2">
          X-linked reticulate pigmentary disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         X-linked reticulate pigmentary disorder with systemic manifestations (XLPDR; MIM #301220) is a very rare genodermatosis caused by mutations in the
         <em>
          POLA1
         </em>
         gene, encoding the catalytic subunit of DNA polymerase-alpha, an essential component of the DNA replication machinery and a critical regulator of the type I interferon response [
         <a href="#rid47">
          47,48
         </a>
         ]. Cells derived from patients with the mutation show increased expression of genes involved in type I interferon signaling pathways and other proinflammatory genes [
         <a href="#rid47">
          47
         </a>
         ]. The disorder was first described in a Canadian family in 1981 and initially called familial cutaneous amyloidosis. Only a few families and one sporadic case have been reported.
        </p>
        <p>
         The affected males have a distinctive facies with upswept frontal hairline and flared eyebrow and present in the first few months of life with recurrent pneumonias, bronchiectasis, chronic diarrhea, and failure to thrive. By early childhood, male patients develop a generalized reticulate hyperpigmentation and hypohidrosis. Additional systemic manifestations include corneal inflammation and scarring, enterocolitis resembling inflammatory bowel disease, and recurrent urethral strictures. These inflammatory manifestations are believed to be autoinflammatory phenomena due to increased production of interferon-alpha and other cytokines [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         In females, XLPDR is characterized by patchy, linear hyperpigmentation following the lines of Blaschko that resemble stage III incontinentia pigmenti, in the absence of systemic manifestations. (See
         <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">
          "Incontinentia pigmenti"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H380523435">
         <span class="h2">
          Naegeli-Franceschetti-Jadassohn syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Naegeli-Franceschetti-Jadassohn syndrome (MIM #161000) is a rare, autosomal dominant form of ectodermal dysplasia caused by heterozygous mutations in the
         <em>
          KRT14
         </em>
         gene at 17q21,2 [
         <a href="#rid49">
          49,50
         </a>
         ]. Clinical features include reticular hyperpigmentation of the skin  (
         <a class="graphic graphic_picture graphicRef111989" href="/z/d/graphic/111989.html" rel="external">
          picture 16
         </a>
         ), palmoplantar keratoderma, absence of dermatoglyphs  (
         <a class="graphic graphic_picture graphicRef111987" href="/z/d/graphic/111987.html" rel="external">
          picture 17
         </a>
         ), hypohidrosis, and heat intolerance. The hyperpigmentation appears in early childhood, increases during the first 10 years of life, and begins to fade around puberty. Dental abnormalities and early tooth loss are common. Nail dystrophy and malalignment can also be seen in these patients.
        </p>
        <p class="headingAnchor" id="H3336641084">
         <span class="h2">
          Dermatopathia pigmentosa reticularis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermatopathia pigmentosa reticularis (MIM #125595) is an autosomal dominant disorder closely related to Naegeli-Franceschetti-Jadassohn syndrome [
         <a href="#rid51">
          51,52
         </a>
         ]. It is caused by mutations in the
         <em>
          KRT14
         </em>
         gene and characterized by the triad of reticulate hyperpigmentation, noncicatricial alopecia, and onychodystrophy. In contrast with Naegeli-Franceschetti-Jadassohn syndrome, there are no dental abnormalities. Variable features include adermatoglyphia, hypohidrosis or hyperhidrosis, and palmoplantar hyperkeratosis [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3281741493">
         <span class="h2">
          Dyskeratosis congenita
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome associated with characteristic mucocutaneous features and an increased risk of developing several malignancies, in particular, squamous cell carcinoma (especially mucosal), acute myelogenous leukemia, and Hodgkin disease
         <sup>
         </sup>
         [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         DC is inherited in an X-linked recessive fashion, but autosomal recessive and dominant forms also have been reported. It is caused by mutations in the
         <em>
          DKC1
         </em>
         gene encoding the protein dyskerin, which is involved in telomerase stabilization and maintenance [
         <a href="#rid55">
          55
         </a>
         ]. Telomerase dysfunction leads to chromosome instability and likely plays a role in tumorigenesis.
        </p>
        <p>
         The mucocutaneous manifestations of DC include  (
         <a class="graphic graphic_picture graphicRef76566" href="/z/d/graphic/76566.html" rel="external">
          picture 18
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A lacy, reticulated pattern of hyperpigmentation involving primarily the neck, upper chest, and upper arms, which develops during the first decade of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nail dystrophy manifesting as longitudinal ridging, splitting, and early pterygium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Teeth anomalies, including malformed, missing, or aberrant spacing  (
         <a class="graphic graphic_picture graphicRef95209" href="/z/d/graphic/95209.html" rel="external">
          picture 19
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukoplakia of the oral mucosa, most often involving the tongue  (
         <a class="graphic graphic_picture graphicRef95211" href="/z/d/graphic/95211.html" rel="external">
          picture 20
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         DC is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1487198178">
         <span class="h2">
          Dyschromatosis symmetrica hereditaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dyschromatosis symmetrica hereditaria is characterized by small, irregular, hyper- and hypopigmented macules on the dorsal aspects of hands and feet  (
         <a class="graphic graphic_picture graphicRef94173" href="/z/d/graphic/94173.html" rel="external">
          picture 21
         </a>
         ) [
         <a href="#rid56">
          56
         </a>
         ]. It is caused by over 200 described mutations in the
         <em>
          ADAR1
         </em>
         gene encoding an adenosine deaminase and shows an autosomal dominant inheritance pattern [
         <a href="#rid57">
          57,58
         </a>
         ]. Most cases are reported from East Asia (Japan, Korea, China), but the disorder has also been observed in European, Afro-Caribbean, and Indian individuals
         <sup>
         </sup>
         [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Most patients develop hyper- and hypopigmented macules by the age of six. Lesions typically increase in size and number until adolescence and then stabilize and persist indefinitely. The diagnosis is clinical. (See
         <a class="medical medical_review" href="/z/d/html/15525.html" rel="external">
          "The dyschromatoses", section on 'Dyschromatosis symmetrica hereditaria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H939798865">
         <span class="h2">
          Dyschromatosis universalis hereditaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dyschromatosis universalis hereditaria (DUH) is a rare disorder characterized by hypo- and hyperpigmented macules in a generalized distribution [
         <a href="#rid60">
          60
         </a>
         ]. It is most frequently seen in East Asian and South Asian countries, particularly in Japan and India [
         <a href="#rid61">
          61
         </a>
         ]. DUH is caused by mutations in the
         <em>
          ABCB6
         </em>
         (ATP-binding cassette subfamily B, member 6) gene and is inherited in an autosomal dominant fashion with variable penetrance [
         <a href="#rid62">
          62,63
         </a>
         ]. Novel mutations of
         <em>
          SASH1
         </em>
         have been identified in Chinese families with DUH [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
         Hypo- and hyperpigmented macules usually appear in the first years of life on the hands and then extend to the face, trunk, and extremities. The diagnosis is clinical. (See
         <a class="medical medical_review" href="/z/d/html/15525.html" rel="external">
          "The dyschromatoses", section on 'Dyschromatosis universalis hereditaria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1468011795">
         <span class="h1">
          DIFFUSE HYPERPIGMENTATION, NONFIGURATE
         </span>
        </p>
        <p class="headingAnchor" id="H3630486809">
         <span class="h2">
          Familial progressive hyperpigmentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial progressive hyperpigmentation (FPH1) is a rare autosomal dominant disorder characterized by irregular patches of cutaneous and mucosal hyperpigmentation that are present either at birth or in early infancy and increase in size and number with age [
         <a href="#rid66">
          66
         </a>
         ]. FPH1 has been mapped to chromosome 19p13.1-pter, although mutations in a specific gene have not been identified [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Familial progressive hyperpigmentation 2 (FPH2; MIM #145250), also called familial progressive hyperpigmentation with or without hypopigmentation or melanosis universalis hereditaria, is rare autosomal dominant disorder with variable penetrance caused by mutations in the
         <em>
          KITLG
         </em>
         gene on chromosome 12q21.32, encoding the C-Kit ligand [
         <a href="#rid68">
          68
         </a>
         ]. FPH2 is characterized by patches of cutaneous hyperpigmentation, café-au-lait macules, and larger, hypopigmented, ash-leaf macules that are present either at birth or in early infancy and increase in size and number with age.
        </p>
        <p class="headingAnchor" id="H448047700">
         <span class="h2">
          Carbon baby
         </span>
         <span class="headingEndMark">
          —
         </span>
         Universal acquired melanosis or "carbon baby" syndrome is an exceedingly rare type of progressive hyperpigmentation of unknown etiology occurring in children [
         <a href="#rid69">
          69,70
         </a>
         ]. The darkening of the skin starts in the first few months of life on the face and limbs and gradually progresses to involve the entire body surface. On histopathology, there is heavy melanin deposition in the basal and suprabasal layers of the epidermis and presence of melanophages in the dermis [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2083263100">
         <span class="h2">
          H syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         H syndrome (MIM #602782) is a rare, multisystem, autoinflammatory disorder mainly affecting patients of Arab and, less commonly, Indian descent [
         <a href="#rid71">
          71
         </a>
         ]. First described in 2008, H syndrome is characterized by cutaneous hyperpigmentation and hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, and short stature [
         <a href="#rid72">
          72,73
         </a>
         ].
        </p>
        <p>
         H syndrome is part of the histiocytosis-lymphadenopathy plus syndrome, which includes three other histiocytic disorders once thought to be separate entities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Faisalabad histiocytosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sinus histiocytosis with massive lymphadenopathy (familial Rosai-Dorfman disease)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome
        </p>
        <p>
        </p>
        <p>
         This group of diseases is caused by homozygous or compound heterozygous mutation in the
         <em>
          SLC29A3
         </em>
         gene on chromosome 10q22, encoding the solute carrier family 29 member 3, also called the equilibrative nucleoside transporter 3, which mediates the uptake of precursors for nucleotide synthesis by salvage pathways. (See
         <a class="medical medical_review" href="/z/d/html/2871.html" rel="external">
          "Peripheral lymphadenopathy in children: Etiology", section on 'Rosai-Dorfman disease'
         </a>
         .)
        </p>
        <p>
         The clinical manifestations of H syndrome are widely variable. Its hallmark is cutaneous hyperpigmentation, which becomes apparent during childhood and is associated with sclerodermatous skin induration and hypertrichosis  (
         <a class="graphic graphic_picture graphicRef111768" href="/z/d/graphic/111768.html" rel="external">
          picture 22
         </a>
         ) [
         <a href="#rid74">
          74
         </a>
         ]. The hyperpigmented and hypertrichotic plaques are located on the middle and lower part of the body.
        </p>
        <p>
         Extracutaneous manifestations may include sensorineural hearing loss, hepatosplenomegaly, short stature, cardiac anomalies (atrial septal defect, ventricular septal defect, mitral valve prolapse, and cardiomegaly), varicose veins, dilated lateral scleral vessels, facial telangiectasias, hallux valgus and fixed flexion contractures of fingers and toes, scrotal masses, and gynecomastia. Membranous nephropathy has been reported in one family [
         <a href="#rid75">
          75
         </a>
         ]. Lymphadenopathy, which may be generalized or localized, has been reported in 24 percent of patients and insulin-dependent diabetes mellitus in 23 percent [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Laboratory abnormalities include mild microcytic anemia, elevated erythrocyte sedimentation rate, elevated liver enzymes, growth hormone deficiency, high gonadotropin levels, and low to normal testosterone levels. A biopsy of the involved skin shows hyperkeratosis, acanthosis, and increased melanin deposition in basal keratinocytes; widespread fibrosis of the dermis and subcutis; and an interstitial inflammatory infiltrate composed of small to medium-sized histiocytes, dendrocytes, plasma cells, lymphocytes, and mast cells  (
         <a class="graphic graphic_picture graphicRef111769" href="/z/d/graphic/111769.html" rel="external">
          picture 23
         </a>
         ) [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         The diagnosis of H syndrome is suspected based upon the clinical findings. Mutational analysis will confirm the diagnosis when there is uncertainty or in patients with mild or incomplete phenotypes. There is no established treatment for H syndrome. Therapies that have been attempted include systemic corticosteroids, immunosuppressive agents, interferon-alpha,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , and radiotherapy [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4277735390">
         <span class="h1">
          GENETIC SYNDROMES ASSOCIATED WITH LENTIGINOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic syndromes associated with lentiginosis are summarized in the table  (
         <a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3088635532">
         <span class="h2">
          Carney complex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carney complex (MIM #160980), previously called LAMB (
         <strong>
          l
         </strong>
         entigines,
         <strong>
          a
         </strong>
         trial myxoma,
         <strong>
          m
         </strong>
         ucocutaneous myxoma,
         <strong>
          b
         </strong>
         lue nevi) or NAME (
         <strong>
          n
         </strong>
         evi,
         <strong>
          a
         </strong>
         trial myxoma,
         <strong>
          m
         </strong>
         yxoid neurofibroma,
         <strong>
          e
         </strong>
         phelides)  (
         <a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">
          table 3
         </a>
         ), is a clinically heterogeneous autosomal dominant disorder characterized by the presence of atrial myxomas, lentigines, skin tumors, and endocrine overactivity. They are caused by mutations in the
         <em>
          PRKAR1A
         </em>
         gene, encoding the protein kinase regulatory subunit 1A, located at 17q22-24.
        </p>
        <p>
         Lentigines occur most commonly on the face, especially on the lips, eyelids, conjunctiva, and oral mucosa  (
         <a class="graphic graphic_picture graphicRef93933" href="/z/d/graphic/93933.html" rel="external">
          picture 24
         </a>
         ), but may be widespread and involve the trunk, extremities, and genitalia
         <sup>
         </sup>
         [
         <a href="#rid78">
          78
         </a>
         ]. Other skin lesions include junctional and compound nevi, blue nevi, and cutaneous myxomas.
        </p>
        <p>
         The diagnostic criteria of Carney complex are summarized in the table  (
         <a class="graphic graphic_table graphicRef83442" href="/z/d/graphic/83442.html" rel="external">
          table 4
         </a>
         ). Given the rarity of this disorder, patients with suspected Carney complex (and their family members) should be referred to specialized centers with expertise in this area for diagnosis and genetic testing [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Carney complex is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/100662.html" rel="external">
          "Carney complex"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1274979321">
         <span class="h2">
          LEOPARD syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         LEOPARD syndrome (MIM #151100), also called Noonan syndrome with multiple lentigines, is a rare, autosomal dominant disorder caused by mutations in the protein tyrosine phosphatase,
         <em>
          PTPN11
         </em>
         gene [
         <a href="#rid80">
          80
         </a>
         ]. LEOPARD is an acronym for the major features of this disorder, including multiple
         <strong>
          l
         </strong>
         entigines,
         <strong>
          e
         </strong>
         lectrocardiogram (ECG) conduction abnormalities,
         <strong>
          o
         </strong>
         cular hypertelorism,
         <strong>
          p
         </strong>
         ulmonic stenosis,
         <strong>
          a
         </strong>
         bnormal genitalia,
         <strong>
          r
         </strong>
         etardation of growth, and sensorineural
         <strong>
          d
         </strong>
         eafness.
        </p>
        <p>
         LEOPARD syndrome belongs to a group of developmental disorders called RAS/MAPK pathway syndromes, which include Noonan syndrome, neurofibromatosis type 1, neurofibromatosis type 1-like syndrome (Legius syndrome), cardiofaciocutaneous syndrome, Costello syndrome, and capillary malformation-arteriovenous malformation syndrome [
         <a href="#rid81">
          81,82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">
          "Capillary malformations (port wine birthmarks) and associated syndromes", section on 'Capillary malformation-arteriovenous malformation syndrome'
         </a>
         .)
        </p>
        <p>
         Multiple lentigines are the most prominent manifestation of LEOPARD syndrome and are present in more than 90 percent of the patients. They appear during infancy and early childhood and increase in number over time to involve a large portion of the skin, including the face  (
         <a class="graphic graphic_picture graphicRef94195" href="/z/d/graphic/94195.html" rel="external">
          picture 25
         </a>
         ), neck, and upper trunk  (
         <a class="graphic graphic_picture graphicRef94195" href="/z/d/graphic/94195.html" rel="external">
          picture 25
         </a>
         ). Lentigines may also occur on the palms, soles, and sclerae. Café-au-lait macules like those found in neurofibromatosis type 1 occur in approximately one-half of the patients.
        </p>
        <p>
         The diagnosis of LEOPARD syndrome is difficult, given the highly variable expressivity of the syndrome. In the first year of life, before the appearance of lentigines, the diagnosis can be clinically suspected in infants presenting with three main features: characteristic facial features, hypertrophic cardiomyopathy, and café-au-lait macules [
         <a href="#rid83">
          83
         </a>
         ]. The diagnosis can be confirmed by molecular screening for
         <em>
          PTPN11
         </em>
         mutations.
        </p>
        <p>
         The management of patients with LEOPARD syndrome requires a multidisciplinary approach involving dermatology, cardiology, endocrinology, and other appropriate specialists. Genetic counseling is indicated and involves clinical and cardiologic examination of parents and molecular analysis if appropriate.
        </p>
        <p class="headingAnchor" id="H75796009">
         <span class="h2">
          Peutz-Jeghers syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peutz-Jeghers syndrome is an autosomal dominant disorder characterized by mucocutaneous lentigines with intestinal polyposis. It is caused by heterozygous mutations in the
         <em>
          STK11/LKB1
         </em>
         tumor suppressor gene, encoding serine/threonine kinase 11.
        </p>
        <p>
         The lentigines are typically present at birth or appear during childhood. They predominantly affect the perioral and periorbital areas but may involve the volar and dorsal aspects of the hands and feet  (
         <a class="graphic graphic_picture graphicRef89492 graphicRef80815 graphicRef89493 graphicRef55335" href="/z/d/graphic/89492.html" rel="external">
          picture 26A-D
         </a>
         ).
        </p>
        <p>
         Mucosal lesions may affect the palate, tongue, buccal mucosa, and conjunctivae. This syndrome is associated with pancreatic carcinoma and ovarian and testicular tumors. The main entity in the differential diagnosis is Laugier-Hunziker syndrome. The diagnosis and management of Peutz-Jeghers syndrome is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15805.html" rel="external">
          "Juvenile polyposis syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1186951481">
         <span class="h2">
          Bannayan-Riley-Ruvalcaba syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare, autosomal dominant, gastrointestinal hamartomatous polyposis syndrome caused by germline mutations in the
         <em>
          PTEN
         </em>
         tumor suppressor gene [
         <a href="#rid84">
          84
         </a>
         ]. It is part of Cowden syndrome-1, also called PTEN hamartoma tumor syndrome or multiple hamartoma syndrome (MIM #158350).
        </p>
        <p>
         The clinical manifestations of BRRS arise early in childhood and include hypotonia, delayed psychomotor development, seizures, diarrhea, intussusception, and anemia. Cutaneous manifestations include genital lentigines, facial verrucae, vascular malformations, lipomas, acanthosis nigricans, and multiple acrochordons. Hyperpigmented macules involving the glans penis  (
         <a class="graphic graphic_picture graphicRef62253" href="/z/d/graphic/62253.html" rel="external">
          picture 27
         </a>
         ) or vulva are the most specific finding related to the syndrome.
        </p>
        <p>
         The diagnosis and management of BRRS are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">
          "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Bannayan-Riley-Ruvalcaba syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H391320714">
         <span class="h1">
          GENETIC SYNDROMES ASSOCIATED WITH CAFÉ-AU-LAIT MACULES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic syndromes associated with café-au-lait macules are summarized in the table  (
         <a class="graphic graphic_table graphicRef94245" href="/z/d/graphic/94245.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2100818934">
         <span class="h2">
          Neurofibromatosis type 1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder caused by a mutation in the
         <em>
          NF1
         </em>
         gene, encoding the protein neurofibromin, a tumor suppressor expressed in many human cells, primarily in neurons, glial, and Schwann cells [
         <a href="#rid85">
          85
         </a>
         ]. Neurofibromin belongs to a family of GTPase-activating proteins (GAPs) that downregulate the cellular proto-oncogenes p21-ras, an important determinant of cell growth and regulation.
        </p>
        <p>
         The presence of six or more café-au-lait macules  (
         <a class="graphic graphic_picture graphicRef96125" href="/z/d/graphic/96125.html" rel="external">
          picture 28
         </a>
         ) (&gt;5 mm in prepubertal individuals and &gt;15 mm in postpubertal individuals), cutaneous neurofibromas  (
         <a class="graphic graphic_picture graphicRef69606 graphicRef94200" href="/z/d/graphic/69606.html" rel="external">
          picture 29A-B
         </a>
         ), and axillary or inguinal freckling  (
         <a class="graphic graphic_picture graphicRef67532" href="/z/d/graphic/67532.html" rel="external">
          picture 30
         </a>
         ) are the hallmark of NF1. Other manifestations of NF1 include plexiform neurofibromas, optic pathway gliomas, and other central and peripheral nervous system tumors.
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of NF1 are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90123.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2912571590">
         <span class="h2">
          Neurofibromatosis type 1-like syndrome (Legius syndrome)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurofibromatosis type 1-like syndrome or Legius syndrome is an autosomal dominant disorder caused by germline loss-of-function mutations in
         <em>
          SPRED1,
         </em>
         encoding a protein that downregulates the RAS/mitogen activated protein kinase (RAS/MAPK) pathway [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
         Clinical features include multiple café-au-lait macules, with or without flexural freckling. Importantly, Legius syndrome lacks neurofibromas and central nervous system tumors. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Legius syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H955292951">
         <span class="h2">
          McCune-Albright syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         McCune-Albright syndrome is a rare mosaic disorder caused by postzygotic activating mutations of the
         <em>
          GNAS1
         </em>
         gene, encoding the alpha subunit of the stimulatory G protein [
         <a href="#rid88">
          88
         </a>
         ]. The syndrome is characterized by the triad of polyostotic fibrous dysplasia, café-au-lait macules, and endocrine hyperactivity, classically causing precocious puberty [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty"
         </a>
         .)
        </p>
        <p>
         The café-au-lait macules appear at birth or shortly after and are the first manifestation of the disease. They have an irregular border described as a "coast of Maine" border and are often unilateral, with midline demarcation and a tendency to follow the Blaschko lines  (
         <a class="graphic graphic_picture graphicRef80844" href="/z/d/graphic/80844.html" rel="external">
          picture 31
         </a>
         and
         <a class="graphic graphic_picture graphicRef94201" href="/z/d/graphic/94201.html" rel="external">
          picture 32
         </a>
         ). Later in life, some patients may develop oral mucosal lentigines [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         There are no effective treatments for hyperpigmented patches associated with McCune-Albright syndrome. The quality-switched (Q-switched) ruby laser has been successfully used in a single patient with facial hyperpigmentation [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2854135364">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Determinants of skin color
         </strong>
         – The color of human skin is mainly determined by the two types of melanin, the black-brown eumelanin and the yellow-red pheomelanin, which are present in individuals of all skin colors, though their ratio is highly variable and determines the hue of the skin. Hyperpigmentation is the darkening or increase in the natural color of the skin, usually due to an increased deposition of melanin (hypermelanosis) in the epidermis and/or dermis. It is a feature of a multitude of clinical conditions, ranging from normal variations of skin color to acquired and inherited syndromes. (See
         <a class="local">
          'Pathophysiology of skin pigmentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – Diagnosis of most hyperpigmentation disorders is made on clinical grounds. The initial patient evaluation involves a detailed medical and family history and a complete skin examination. Important clinical parameters include the extent of the pigmentary abnormality, color hue and morphology of individual lesions, distribution, and pattern. An algorithmic approach to the diagnosis based upon history and clinical parameters is shown in the figure  (
         <a class="graphic graphic_algorithm graphicRef93949" href="/z/d/graphic/93949.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Patient evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Localized versus diffuse hyperpigmentation
         </strong>
         – Congenital and inherited hyperpigmentation disorders may be localized (eg, congenital dermal melanocytosis, café-au-lait macule) or diffuse. The latter often show a linear configuration that follows the lines of Blaschko (eg, incontinentia pigmenti, linear and whorled nevoid hypermelanosis) or a reticular pattern (eg, Dowling-Degos disease, reticulate acropigmentation of Kitamura, dyskeratosis congenita). (See
         <a class="local">
          'Circumscribed hyperpigmentation'
         </a>
         above and
         <a class="local">
          'Diffuse linear hyperpigmentation'
         </a>
         above and
         <a class="local">
          'Diffuse reticular hyperpigmentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic syndromes associated with lentiginosis and café-au-lait macules
         </strong>
         – Multiple lentigines and café-au-lait macules are the hallmark of several genetic syndromes. Carney complex, LEOPARD (multiple
         <strong>
          l
         </strong>
         entigines,
         <strong>
          e
         </strong>
         lectrocardiogram [ECG] conduction abnormalities,
         <strong>
          o
         </strong>
         cular hypertelorism,
         <strong>
          p
         </strong>
         ulmonic stenosis,
         <strong>
          a
         </strong>
         bnormal genitalia,
         <strong>
          r
         </strong>
         etardation of growth, and sensorineural
         <strong>
          d
         </strong>
         eafness) syndrome, and Peutz-Jeghers syndrome are associated with lentiginosis. Genetic syndromes associated with café-au-lait macules include neurofibromatosis type 1, Legius syndrome, and McCune-Albright syndrome. (See
         <a class="local">
          'Genetic syndromes associated with lentiginosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, 2012. Vol 1, p.804.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis 2007; 80:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol 2014; 13:401.
          </a>
         </li>
         <li class="breakAll">
          Ito S, Wakamatsu K. Chemistry of melanins. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, 2006. p.282.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet 2009; 18:R9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturm RA, Duffy DL. Human pigmentation genes under environmental selection. Genome Biol 2012; 13:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speeckaert R, Van Gele M, Speeckaert MM, et al. The biology of hyperpigmentation syndromes. Pigment Cell Melanoma Res 2014; 27:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delevoye C. Melanin transfer: the keratinocytes are more than gluttons. J Invest Dermatol 2014; 134:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46:S41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szabó G, Gerald AB, Pathak MA, Fitzpatrick TB. Racial differences in the fate of melanosomes in human epidermis. Nature 1969; 222:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranu H, Thng S, Goh BK, et al. Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification. Dermatol Surg 2011; 37:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picardo M, Cardinali G. The genetic determination of skin pigmentation: KITLG and the KITLG/c-Kit pathway as key players in the onset of human familial pigmentary diseases. J Invest Dermatol 2011; 131:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hershkovitz D, Sprecher E. Monogenic pigmentary skin disorders: genetics and pathophysiology. Isr Med Assoc J 2008; 10:713.
          </a>
         </li>
         <li class="breakAll">
          Ortonne JP, Nordlund JJ. Mechanisms that cause abnormal skin color. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, 2006. p.521.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuh AA, Wong WC, Wong SY, Lee A. Procedures in primary care dermatology. Aust Fam Physician 2005; 34:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005; 27:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilchrest BA, Fitzpatrick TB, Anderson RR, Parrish JA. Localization of malanin pigmentation in the skin with Wood's lamp. Br J Dermatol 1977; 96:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amatya B. Evaluation of Dermoscopic Features in Facial Melanosis with Wood Lamp Examination. Dermatol Pract Concept 2022; 12:e2022030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polder KD, Landau JM, Vergilis-Kalner IJ, et al. Laser eradication of pigmented lesions: a review. Dermatol Surg 2011; 37:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogeling M, Frieden IJ. Segmental pigmentation disorder. Br J Dermatol 2010; 162:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torchia D, Happle R. Segmental hypomelanosis and hypermelanosis arranged in a checkerboard pattern are distinct naevi: flag-like hypomelanotic naevus and flag-like hypermelanotic naevus. J Eur Acad Dermatol Venereol 2015; 29:2088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oren-Shabtai M, Metzker A, Ben Amitai D, et al. Segmental Pigmentation Disorder: Clinical Manifestations and Epidemiological Features in 144 patients, a Retrospective Case-control Study. Acta Derm Venereol 2022; 102:adv00707.
          </a>
         </li>
         <li class="breakAll">
          Nordlund JJ, Ortonne JP. The normal color of human skin. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang R, Zhu W. Coexistence of pigmentary demarcation lines types C and E in one subject. Int J Dermatol 2011; 50:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalter DC, Griffiths WA, Atherton DJ. Linear and whorled nevoid hypermelanosis. J Am Acad Dermatol 1988; 19:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lernia V. Linear and whorled hypermelanosis. Pediatr Dermatol 2007; 24:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi Z, Duan X, Jiang M, et al. Treatment of linear and whorled nevoid hypermelanosis using QS 694-nm ruby laser. J Cosmet Laser Ther 2022; 24:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann A, Hofmann UB, Hoehn H, et al. Postnatal confirmation of prenatally diagnosed trisomy 20 mosaicism in a patient with linear and whorled nevoid hypermelanosis. Pediatr Dermatol 2004; 21:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verghese S, Newlin A, Miller M, Burton BK. Mosaic trisomy 7 in a patient with pigmentary abnormalities. Am J Med Genet 1999; 87:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubota Y, Shimura Y, Shimada S, et al. Linear and whorled nevoid hypermelanosis in a child with chromosomal mosaicism. Int J Dermatol 1992; 31:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betz RC, Planko L, Eigelshoven S, et al. Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease. Am J Hum Genet 2006; 78:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basmanav FB, Fritz G, Lestringant GG, et al. Pathogenicity of POFUT1 in Dowling-Degos disease: additional mutations and clinical overlap with reticulate acropigmentation of kitamura. J Invest Dermatol 2015; 135:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basmanav FB, Oprisoreanu AM, Pasternack SM, et al. Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease. Am J Hum Genet 2014; 94:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson NJ, Cole C, Kroboth K, et al. Mutations in POGLUT1 in Galli-Galli/Dowling-Degos disease. Br J Dermatol 2017; 176:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li CR, Brooks YS, Jia WX, et al. Pathogenicity of POFUT1 mutations in two Chinese families with Dowling-Degos disease. J Eur Acad Dermatol Venereol 2016; 30:e79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naveen KN, Athaniker SB, Hegde SP, et al. Atypical cases of Dowling-Degos disease. Indian Dermatol Online J 2016; 7:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YC, Davis MD, Schanbacher CF, Su WP. Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases. J Am Acad Dermatol 1999; 40:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishizawa A, Nakano H, Satoh T, et al. Haber's syndrome may be a clinical entity different from Dowling-Degos disease. Br J Dermatol 2009; 160:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reisenauer AK, Wordingham SV, York J, et al. Heterozygous frameshift mutation in keratin 5 in a family with Galli-Galli disease. Br J Dermatol 2014; 170:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmieder A, Pasternack SM, Krahl D, et al. Galli-Galli disease is an acantholytic variant of Dowling-Degos disease: additional genetic evidence in a German family. J Am Acad Dermatol 2012; 66:e250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Haseni AG, Ho JD, Maymone MB, et al. Generalized Dyschromia and Erythematous Papules in a 66-Year-Old Man: Challenge. Am J Dermatopathol 2019; 41:e3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenzel G, Petrow W, Tappe K, et al. Treatment of Dowling-Degos disease with Er:YAG-laser: results after 2.5 years. Dermatol Surg 2003; 29:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yun JH, Kim JH, Choi JS, et al. Treatment of Dowling-Degos disease with fractional Er:YAG laser. J Cosmet Laser Ther 2013; 15:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Sugiura K, Suganuma M, et al. Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease. Hum Mol Genet 2013; 22:3524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang JC, Escandon J, Shiman M, Berman B. Presentation of reticulate acropigmentation of kitamura and dowling-degos disease overlap. J Clin Aesthet Dermatol 2012; 5:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kameyama K, Morita M, Sugaya K, et al. Treatment of reticulate acropigmentation of Kitamura with azelaic acid. An immunohistochemical and electron microscopic study. J Am Acad Dermatol 1992; 26:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol 2016; 17:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pezzani L, Brena M, Callea M, et al. X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature. Am J Med Genet A 2013; 161A:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lugassy J, McGrath JA, Itin P, et al. KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome. J Invest Dermatol 2008; 128:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lugassy J, Itin P, Ishida-Yamamoto A, et al. Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. Am J Hum Genet 2006; 79:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heimer WL 2nd, Brauner G, James WD. Dermatopathia pigmentosa reticularis: a report of a family demonstrating autosomal dominant inheritance. J Am Acad Dermatol 1992; 26:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger B, Spoerri I, Imahorn E, et al. Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: intrafamilial overlap of phenotypes in patients with the same KRT14 frameshift variant. Br J Dermatol 2019; 181:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Saif F. Dermatopathia Pigmentosa Reticularis: Report of a New Cases and Literature Review. Indian J Dermatol 2016; 61:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011; 2011:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight SW, Heiss NS, Vulliamy TJ, et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999; 65:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi M, Suzuki T. Dyschromatosis symmetrica hereditaria. J Dermatol 2013; 40:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyamura Y, Suzuki T, Kono M, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet 2003; 73:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang P, Yu S, Liu J, et al. Seven novel mutations of ADAR in multi-ethnic pedigrees with dyschromatosis symmetrica hereditaria in China. Mol Genet Genomic Med 2019; 7:e00905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyama M, Shimizu H, Ohata Y, et al. Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. Br J Dermatol 1999; 140:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Mahajan BB, Singh R Jr. Dyschromatosis universalis hereditaria: a rare entity. Dermatol Online J 2011; 17:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Hawsawi K, Al Aboud K, Ramesh V, Al Aboud D. Dyschromatosis universalis hereditaria: report of a case and review of the literature. Pediatr Dermatol 2002; 19:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Li D, Zhang J, et al. Mutations in ABCB6 cause dyschromatosis universalis hereditaria. J Invest Dermatol 2013; 133:2221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu H, Li Y, Hung KK, et al. Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria. PLoS One 2014; 9:e87250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao L, Zhang R, Yong L, et al. Novel missense mutation of SASH1 in a Chinese family with dyschromatosis universalis hereditaria. BMC Med Genomics 2021; 14:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu JW, Habulieti X, Wang RR, et al. Two novel SASH1 mutations in Chinese families with dyschromatosis universalis hereditaria. J Clin Lab Anal 2021; 35:e23803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanardo L, Stolz W, Schmitz G, et al. Progressive hyperpigmentation and generalized lentiginosis without associated systemic symptoms: a rare hereditary pigmentation disorder in south-east Germany. Acta Derm Venereol 2004; 84:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Deng Y, Chen X, et al. Linkage of a locus determining familial progressive hyperpigmentation (FPH) to chromosome 19p13.1-pter in a Chinese family. Eur J Dermatol 2006; 16:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amyere M, Vogt T, Hoo J, et al. KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol 2011; 131:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh SK, Ghoshal L, Bhunia D, Ghoshal AM. Acquired universal melanosis (carbon baby syndrome). Pediatr Dermatol 2014; 31:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Maldonado R, Tamayo L, Fernández-Diez J. Universal acquired melanosis. The carbon baby. Arch Dermatol 1978; 114:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yesudian P, Sarveswari KN, Karrunya KJ, Thomas K. H Syndrome - A Case Report. Indian Dermatol Online J 2019; 10:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molho-Pessach V, Agha Z, Aamar S, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol 2008; 59:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tekin B, Atay Z, Ergun T, et al. H syndrome: a multifaceted histiocytic disorder with hyperpigmentation and hypertrichosis. Acta Derm Venereol 2015; 95:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molho-Pessach V, Ramot Y, Camille F, et al. H syndrome: the first 79 patients. J Am Acad Dermatol 2014; 70:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           David O, Geylis M, Kristal E, et al. Glomerular involvement in children with H syndrome. Pediatr Nephrol 2021; 36:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doviner V, Maly A, Ne'eman Z, et al. H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases. Am J Dermatopathol 2010; 32:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011; 10:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy PM, Piehler JM, Schaff HV, et al. The significance of multiple, recurrent, and "complex" cardiac myxomas. J Thorac Cardiovasc Surg 1986; 91:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86:4041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008; 3:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rauen KA, Schoyer L, McCormick F, et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 2010; 152A:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Digilio MC, Sarkozy A, de Zorzi A, et al. LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet A 2006; 140:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah KR, Boland CR, Patel M, et al. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol 2013; 68:189.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009; 61:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brems H, Pasmant E, Van Minkelen R, et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat 2012; 33:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denayer E, Chmara M, Brems H, et al. Legius syndrome in fourteen families. Hum Mutat 2011; 32:E1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 2012; 7 Suppl 1:S4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichard DC, Boyce AM, Collins MT, Cowen EW. Oral pigmentation in McCune-Albright syndrome. JAMA Dermatol 2014; 150:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozawa T, Tateishi C, Shirakawa M, et al. Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser. Dermatol Surg 2011; 37:263.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 111807 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, 2012. Vol 1, p.804.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18189024" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Common dermatologic disorders in skin of color: a comparative practice survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24719058" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Dyschromia in skin of color.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24719058" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Dyschromia in skin of color.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297406" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular genetics of human pigmentation diversity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23110848" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Human pigmentation genes under environmental selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612852" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The biology of hyperpigmentation syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24646798" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Melanin transfer: the keratinocytes are more than gluttons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11807469" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Skin of color: biology, structure, function, and implications for dermatologic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5787098" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Racial differences in the fate of melanosomes in human epidermis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21682796" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21566575" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The genetic determination of skin pigmentation: KITLG and the KITLG/c-Kit pathway as key players in the onset of human familial pigmentary diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19009952" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Monogenic pigmentary skin disorders: genetics and pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19009952" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Monogenic pigmentary skin disorders: genetics and pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15887937" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Procedures in primary care dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15798432" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/857837" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Localization of malanin pigmentation in the skin with Wood's lamp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35223174" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Evaluation of Dermoscopic Features in Facial Melanosis with Wood Lamp Examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21492309" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Laser eradication of pigmented lesions: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20163411" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Segmental pigmentation disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25752916" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Segmental hypomelanosis and hypermelanosis arranged in a checkerboard pattern are distinct naevi: flag-like hypomelanotic naevus and flag-like hypermelanotic naevus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35312024" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Segmental Pigmentation Disorder: Clinical Manifestations and Epidemiological Features in 144 patients, a Retrospective Case-control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35312024" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Segmental Pigmentation Disorder: Clinical Manifestations and Epidemiological Features in 144 patients, a Retrospective Case-control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21699524" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Coexistence of pigmentary demarcation lines types C and E in one subject.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3204178" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Linear and whorled nevoid hypermelanosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17542865" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Linear and whorled hypermelanosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35430930" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of linear and whorled nevoid hypermelanosis using QS 694-nm ruby laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15575846" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Postnatal confirmation of prenatally diagnosed trisomy 20 mosaicism in a patient with linear and whorled nevoid hypermelanosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10594873" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mosaic trisomy 7 in a patient with pigmentary abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1587665" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Linear and whorled nevoid hypermelanosis in a child with chromosomal mosaicism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16465624" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25229252" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pathogenicity of POFUT1 in Dowling-Degos disease: additional mutations and clinical overlap with reticulate acropigmentation of kitamura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24387993" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27479915" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mutations in POGLUT1 in Galli-Galli/Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26486618" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pathogenicity of POFUT1 mutations in two Chinese families with Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27057490" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Atypical cases of Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10071319" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19067693" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Haber's syndrome may be a clinical entity different from Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24372084" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Heterozygous frameshift mutation in keratin 5 in a family with Galli-Galli disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22583733" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Galli-Galli disease is an acantholytic variant of Dowling-Degos disease: additional genetic evidence in a German family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475510" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Generalized Dyschromia and Erythematous Papules in a 66-Year-Old Man: Challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14641349" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of Dowling-Degos disease with Er:YAG-laser: results after 2.5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23464495" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment of Dowling-Degos disease with fractional Er:YAG laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23666529" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22808308" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Presentation of reticulate acropigmentation of kitamura and dowling-degos disease overlap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1613143" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment of reticulate acropigmentation of Kitamura with azelaic acid. An immunohistochemical and electron microscopic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27019227" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : DNA polymerase-αregulates the activation of type I interferons through cytosolic RNA:DNA synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23613254" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18049449" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16960809" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1303619" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dermatopathia pigmentosa reticularis: a report of a family demonstrating autosomal dominant inheritance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30968399" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: intrafamilial overlap of phenotypes in patients with the same KRT14 frameshift variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27512211" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Dermatopathia Pigmentosa Reticularis: Report of a New Cases and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22160078" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Dyskeratosis congenita.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10364516" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22974014" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12916015" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31423758" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Seven novel mutations of ADAR in multi-ethnic pedigrees with dyschromatosis symmetrica hereditaria in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233273" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810391" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Dyschromatosis universalis hereditaria: a rare entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12437556" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Dyschromatosis universalis hereditaria: report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23519333" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mutations in ABCB6 cause dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24498303" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34174894" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Novel missense mutation of SASH1 in a Chinese family with dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34028087" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Two novel SASH1 mutations in Chinese families with dyschromatosis universalis hereditaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15040480" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Progressive hyperpigmentation and generalized lentiginosis without associated systemic symptoms: a rare hereditary pigmentation disorder in south-east Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16709486" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Linkage of a locus determining familial progressive hyperpigmentation (FPH) to chromosome 19p13.1-pter in a Chinese family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21368769" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : KITLG mutations cause familial progressive hyper- and hypopigmentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23331086" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Acquired universal melanosis (carbon baby syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/646402" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Universal acquired melanosis. The carbon baby.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31149577" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : H Syndrome - A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18410979" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26015165" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : H syndrome: a multifaceted histiocytic disorder with hyperpigmentation and hypertrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24172204" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : H syndrome: the first 79 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33387019" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Glomerular involvement in children with H syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20010285" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21538076" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The differential diagnosis of familial lentiginosis syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3951243" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The significance of multiple, recurrent, and "complex" cardiac myxomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11549623" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18505544" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Leopard syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19467855" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20014119" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16523510" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : LEOPARD syndrome: clinical diagnosis in the first year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23317980" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Cutaneous manifestations of gastrointestinal disease: part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19539839" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753041" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Review and update of SPRED1 mutations causing Legius syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21089071" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Legius syndrome in fourteen families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944469" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22640971" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24671640" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Oral pigmentation in McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21272121" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
